These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21526201)

  • 21. CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo.
    Tan YJ; Lim SP; Ng P; Goh PY; Lim SG; Tan YH; Hong W
    Virology; 2003 Apr; 308(2):250-69. PubMed ID: 12706076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.
    Qin ZL; Ju HP; Gao TT; Wang WB; Ren H; Zhao P; Qi ZT
    J Gen Virol; 2015 Jun; 96(Pt 6):1389-1399. PubMed ID: 25701820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection.
    Ishibashi M; Morita N; Nomura-Kawaguchi C; Shimizu Y; Wakita T; Esumi M
    Arch Virol; 2014 Nov; 159(11):2949-55. PubMed ID: 24965233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.
    Bertaux C; Dragic T
    J Virol; 2006 May; 80(10):4940-8. PubMed ID: 16641285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
    Keck ZY; Xia J; Cai Z; Li TK; Owsianka AM; Patel AH; Luo G; Foung SK
    J Virol; 2007 Jan; 81(2):1043-7. PubMed ID: 17079294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.
    Masciopinto F; Campagnoli S; Abrignani S; Uematsu Y; Pileri P
    Virus Res; 2001 Nov; 80(1-2):1-10. PubMed ID: 11597743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
    Witteveldt J; Evans MJ; Bitzegeio J; Koutsoudakis G; Owsianka AM; Angus AG; Keck ZY; Foung SK; Pietschmann T; Rice CM; Patel AH
    J Gen Virol; 2009 Jan; 90(Pt 1):48-58. PubMed ID: 19088272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection.
    Crotta S; Brazzoli M; Piccioli D; Valiante NM; Wack A
    J Hepatol; 2010 Feb; 52(2):183-90. PubMed ID: 20015567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.
    Crotta S; Stilla A; Wack A; D'Andrea A; Nuti S; D'Oro U; Mosca M; Filliponi F; Brunetto RM; Bonino F; Abrignani S; Valiante NM
    J Exp Med; 2002 Jan; 195(1):35-41. PubMed ID: 11781363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.
    Koutsoudakis G; Herrmann E; Kallis S; Bartenschlager R; Pietschmann T
    J Virol; 2007 Jan; 81(2):588-98. PubMed ID: 17079281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
    Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
    PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
    Zhang J; Randall G; Higginbottom A; Monk P; Rice CM; McKeating JA
    J Virol; 2004 Feb; 78(3):1448-55. PubMed ID: 14722300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.
    Rothwangl KB; Rong L
    Virol J; 2009 Jan; 6():12. PubMed ID: 19171049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
    Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
    Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.
    Owsianka A; Clayton RF; Loomis-Price LD; McKeating JA; Patel AH
    J Gen Virol; 2001 Aug; 82(Pt 8):1877-1883. PubMed ID: 11457993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
    Machida K; Kondo Y; Huang JY; Chen YC; Cheng KT; Keck Z; Foung S; Dubuisson J; Sung VM; Lai MM
    J Virol; 2008 Jul; 82(13):6711-20. PubMed ID: 18417597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81.
    Tian ZF; Shen H; Fu XH; Chen YC; Blum HE; Baumert TF; Zhao XP
    World J Gastroenterol; 2009 Jan; 15(2):240-4. PubMed ID: 19132776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule inhibition of hepatitis C virus E2 binding to CD81.
    VanCompernolle SE; Wiznycia AV; Rush JR; Dhanasekaran M; Baures PW; Todd SC
    Virology; 2003 Sep; 314(1):371-80. PubMed ID: 14517089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.